Impressive Continuous Complete Response after Mogamulizumab in a Heavily Pretreated Sézary Syndrome Patient

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Sézary syndrome (SS) is a rare, aggressive cutaneous T-cell lymphoma with limited treatment options.
• Relapsed/refractory SS patients face poor prognoses with conventional therapies offering only short-term remission.
• The MAVORIC trial established mogamulizumab's efficacy against vorinostat in SS.

Observation:

• A heavily pretreated 57-year-old woman with stage IVA SS received mogamulizumab.
• She achieved a rapid response but discontinued therapy after 30 cycles due to cutaneous toxicity.
• Remarkably, the patient has maintained a complete response (CR) long-term.

Findings:

• Mogamulizumab, a CCR4-targeting monoclonal antibody, can induce sustained responses in SS.
• Complete response was achieved and maintained despite treatment cessation.
• The patient remains in CR 2.5 years after discontinuing mogamulizumab therapy.

Implications:

• Mogamulizumab represents a promising therapeutic option for heavily pretreated SS patients.
• Long-lasting remissions are achievable, even in cases requiring treatment discontinuation.
• This case highlights the potential for durable efficacy of anti-CCR4 therapy in advanced cutaneous lymphomas.